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(€15,398 vs. €8614; p0.016) than patients without these co-morbidities. Indirect
costs were also higher in PD patients with these co-morbidities than patients with
PD alone; the difference being significant only for dementia (€8201 vs. €2964;
p0.037). CONCLUSIONS: Co-morbid dyskinesia, dementia, or depression were
observed to be the major contributors to the fiscal burden of PD in Germany, post-
2000. An overall increase in the (estimated) costs associated with these co-morbid-
ities was evident during the time-period evaluated. Further studies to understand
the cause of increased (estimated) costs associated with these co-morbidities in PD
are warranted.
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OBJECTIVES: Multiple sclerosis (MS) is a chronic, neurodegenerative inflammatory
disease of the central nervous system. In Spain, the prevalence rate of MS is esti-
mated to range between 53 and 58 cases per 100,000. At disease onset, relapsing-
remitting MS (RRMS) is diagnosed in approximately 60% to 85% of MS patients.
Based on the available evidence, pharmacological costs of disease modifying drugs
(DMD) represent the highest proportion of direct health care costs. In order to
ensure sustainability of the health system is crucial to analyze pharmacological
cost of DMD used in the treatment of RRMS from the perspective of the health
system. METHODS: A direct medical costs analysis model was developed to assess
pharmacological costs per patient and year of treatment with DMD. Therapeutic
alternatives assessed were: interferon (IFN) -1a intramuscular, IFN -1a subcuta-
neous 22 g, IFN -1a subcutaneous 44 g, IFN -1b subcutaneous, IFN  1-b sub-
cutaneous, glatiramer acetate, natalizumab and fingolimod. Dosages for each drug
were those described in summary product characteristics. Pharmacological costs
were obtained from database of General Council of Official Colleges of Pharmacists
(BotPlus) consulted at May 2012. Costs were expressed as ex-factory price applying
7.5% discount according to RDL 8/2010. RESULTS: Pharmacological costs per pa-
tient and year of treatment for each one of the therapeutic alternatives assessed
were: 10,050.74€ for IFN -1a im; 9,357.23€ for IFN -1a sc 22g; 14,035.64€ for IFN
-1a sc 44g; 9,761.56€ for IFN -1b sc; 9,420.38€ for glatiramer acetate; 19,683.12€
for natalizumab and 19,292.90€ for fingolimod. CONCLUSIONS: Due to actual so-
cioeconomic climate and the recent measures of pharmaceutical costs contain-
ment, when selecting the most appropriate therapeutic option additionally to ef-
ficiency criteria, the economic impact on pharmacy services should be also
considered. This analysis is particularly relevant in the case of chronic diseases
with a high socioeconomic impact, as the RRMS.
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OBJECTIVES: There is a lack of long-term prospective data to document the eco-
nomic burden (direct and indirect costs) of Alzheimer’s disease (AD), especially in
moderate AD where disease management becomes more complex. The EVOCOST
study aims to describe and analyse the health care resource use and costs associ-
ated with clinical evolution in a cohort of moderate AD patients in routine medical
practice in Spain. METHODS: The EVOCOST study is a prospective 12-month mul-
ticentre cohort study recruiting community-dwelling moderate AD patients in
Spain. Health care resources (specialist, general practitioner and nurses visits, hos-
pitalisations and emergency room visits, antidementia drugs and institutionalisa-
tion) and non-health care resources (caregiver’s time for care and supervision)
were collected retrospectively. Total costs over the entire 12-month study fol-
low-up were calculated. Costs over the 3 months preceding baseline and the end of
follow-up were compared. RESULTS: A total of 209 patients were included at base-
line, 76.1% of them were women, with a mean age of 78.4 years and a mean MMSE
of 15.2. Over the entire 12-month study follow-up, the mean monthly cost per
patient was €1016 (annual cost €12197). The major cost driver was the informal
caregiver time dedicated to patient supervision and care (€852, 84% of total cost).
Other costs were as follows: antidementia drugs (€88, 9%), hospitalisation and
emergency room visits (€31, 3%), visits (€26, 3%) and institutionalisation (€20,
2%).The mean monthly cost per patient increased significantly during the 12-
month study follow-up from €902 to €1074 (	cost19%, p0.001), mainly due to
the increase in caregiver time. CONCLUSIONS: Management of community-dwell-
ing moderate AD patients in Spain is associated with a high monthly cost ( €1000/
month). The main cost driver is by far the caregiver time which is not reimbursed
by health insurance. The EVOCOST study results illustrate the economic burden of
Alzheimer’s disease on patients’ caregivers.
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OBJECTIVES:Multiple sclerosis (MS) is a chronic autoimmune disease of the central
nervous system that results in resistant incapacitation in absence of appropriate
therapy, considerably reducing patients’ qualities of life. The average number of
patients with MS reaches 2,5 million patients in the world and about 500 000 pa-
tients in Russia. METHODS: Patients registry of the follow-up care in the Clinical
and Diagnostic Center Of Demyelinating Diseases of the Tatarstan Republic be-
came the source of data on real clinical practice of maintaining patients. RESULTS:
Total number of patients – 756; 72% of them - female, 60 % developed remitting type
of MS, average disease duration – 10.3 years, average patients age – 41. During the
cost of illness analysis of MS we estimated direct costs and indirect costs. Direct
costs included diagnostics at the out-patient (24.2 Euro per year) and in-patient
department (28.98 Euro per year), medical services and pharmacotherapy during
the residence in the in-patient department (15.7 Euro per year). Average duration of
residence in the in-patient department in the care of relapse made 15 days; costs
for the residence amounted 155.5 Euro per year. The highest priced stage of pa-
tients case management is the follow-up pharmacotherapy with disease modifying
drugs (DMD’s) that amounted about 4 849.06 Euro per year. Indirect costs included
disability grant (441.7 Euro per year), GDP waste in case of absence at the working
place (146.9 per year) and in case of forced work refusal of patients (4 182.9 Euro per
year) or their relatives (2 423,9 Euro per year) and social worker help (251.9 Euro per
year). CONCLUSIONS: Cost of illness analysis of MS showed that the highest priced
stages are DMD’s therapy and GDP waste. Total direct costs amounted 5 367.9 Euro per
year, indirect costs – 7 195.6 Euro per year. Total costs amounted 12 563,62 Euro per year.
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Multiple sclerosis (MS) is a multifocal central nervous system disorder character-
ised by inflammatory demyelinating lesions affecting white and grey matter. MS
affects quality of life of the patients and requires costy and long term treatments.
OBJECTIVES: To determine the direct medical costs incurred in the treatment of
relapsing remitting MS patients in the Social Security Mexican Institute (IMSS).
METHODS: The data for this analysis were abstracted from the IMSS records, to be
included each patient had to have at least 1 medical claim with a diagnosis of MS
between January 1, 2008 and December 31, 2008. The patients records were used to
obtain resource utilization over the year (including prescription drugs, clinician
visits, surgical procedures, diagnostic procedures, etc), the costs were obtained
from the IMSS public lists and were actualized to 2011 costs. RESULTS: A total of
172 patients were identified with a MS code, 52.33% (n90) of them met the criteria
for relapsing remitting MS. There were 54 female patients, with a female:male ratio
of 1.5:1, with a mean evolution time of 7.21 years. The total average annual cost for
each patient was MxP $173.970,64, 81.31% of which was attributable to the cost of
prescription drugs, (80.5% was associated to the cost of disease-modifying drugs in
particular (including interferon beta 1b, interferon beta 1a and glatiramer acetate);
16.2% to outpatient care (diagnostic and treatment-related procedures, office visit
charges for usual care), 1.3% to inpatient care (diagnostic or treatment-related
procedures, room and board charges, clinician inpatient visit and surgical proce-
dures) and 1.16% to emergency room care (associated to disease exacerbation
mainly). CONCLUSIONS: This analysis shows that prescription drug accounted for
81.31% of total relapsing-remitting MS related medical direct costs in the Mexican
setting and that this costs are mainly associated with the use of disease-modifying
drugs.
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OBJECTIVES: To describe economic burden for persons with SB in Germany.
METHODS: Survey data were used to capture use of health care and assistive
technologies for both last year and ten years prior to data collection. Participants
were recruited from the tertiary clinic database or when initiating care in the clinic.
Participants had to have a verifiable SB diagnosis, and a cognitive ability to respond
to the questionnaire or a caregiver able to answer questions. Data were double-
entered with queries issued to patients to improve data quality. Descriptive anal-
yses were used to summarize data. RESULTS: Information on resource use for 88
participants was collected (44% female, mean age 28.7, SD13.5). In the year prior
to data collection, 88.6% (N78) had at least one visit to a general practitioner (GP),
77.3% (N68) a visit to urologist, and 69.3% (N61) a visit to physiotherapist. Mean
number of annual visits was 7.6 GP, 3.6 urologist, and 65.3 physiotherapist visits.
Participants reporting secondary care use were found to visit hospital most often
(N38, 43.2%), followed by emergency room care (N12, 13.6%). Among responders
being hospitalized, average annual length of stay in a regular ward was 14.8 days
per person, with average hospitalization of 7.3 days. During previous ten years,
majority of responders required a wheelchair (N59, 67.0%), glasses (N57, 64.7%),
and orthopaedic shoes (N52, 59.1%), with an average of 2.5, 2.8, and 6.1 new items
respectively. CONCLUSIONS: Results indicate that persons with SB require a sub-
stantial amount of health care both in short and long term and that the overall
burden experienced by persons with SB may be high, especially if coupled by pos-
sible quality of life implications. Successful prevention, using education and tar-
geted intervention for women of childbearing age could reduce the burden, but
further research is required to fully understand economic impact of SB.
A549V A L U E I N H E A L T H 1 5 ( 2 0 1 2 ) A 2 7 7 – A 5 7 5
